“David’s invaluable licensing and strategic collaborations experience, particularly in the biotech, digital health, and medical device fields, enhances our lifecycle offering which advises over 1,700 global life sciences clients spanning from big pharma to emerging companies,” said Mitchell Bloom, Chair of Goodwin’s Life Sciences practice. “We are thrilled to welcome David to the firm as he joins our team on the West Coast.”
David advises clients in the life sciences and technology industries in strategic collaborations and partnerships, joint ventures, intellectual property transactions, general commercial matters, and data protection and privacy matters. He also advises private equity funds and other financial institutions in investment and financing transactions, mergers and acquisitions, and foreign direct investments in the APAC region, including in China, Japan, and South Korea. David specializes in advising U.S. and foreign pharmaceutical, biotechnology, digital health, and medical device companies of all stages, from start-ups to emerging companies to large multinationals, on their transactions encompassing the entire value chain. David is an expert on cross-border collaboration and licensing transactions and relocates to his native California after spending 15+ years in China.
Goodwin’s Life Sciences practice works with companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The Healthcare private equity and regulatory practice advises private equity firms and their portfolio companies, providers, digital health companies, women’s health and wellness companies, and investors on transactions, regulations, government investigations, and litigation.